Cancer Cachexia - Pipeline Review, H2 2015
Summary
Global Markets Directs, Cancer Cachexia - Pipeline Review, H2 2015, provides an overview of the Cancer Cachexias therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cancer Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cancer Cachexia Overview 9
Therapeutics Development 10
Pipeline Products for Cancer Cachexia - Overview 10
Pipeline Products for Cancer Cachexia - Comparative Analysis 11
Cancer Cachexia - Therapeutics under Development by Companies 12
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 14
Cancer Cachexia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cancer Cachexia - Products under Development by Companies 18
Cancer Cachexia - Products under Investigation by Universities/Institutes 20
Cancer Cachexia - Companies Involved in Therapeutics Development 21
Acacia Pharma Limited 21
Aeterna Zentaris Inc. 22
Amgen Inc. 23
Aphios Corporation 24
Atara Biotherapeutics, Inc. 25
Eli Lilly and Company 26
GTx, Inc. 27
Helsinn Healthcare S.A. 28
Incyte Corporation 29
KAEL-GemVax Co., Ltd. 30
Novartis AG 31
Obexia AG 32
PsiOxus Therapeutics Limited 33
Radius Health, Inc. 34
RaQualia Pharma Inc. 35
Rhythm Pharmaceuticals 36
Vicus Therapeutics, LLC 37
Viking Therapeutics, Inc. 38
Cancer Cachexia - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(etodolac + propranolol hydrochloride) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(formoterol fumarate + megestrol acetate) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
anamorelin hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ATA-842 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
bimagrumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
C-1889 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
dronabinol - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
enobosarm - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Espindolol - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
EXT-400 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
landogrozumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
macimorelin acetate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
NBD Peptide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
OBX-1201 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RAD-140 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
relamorelin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RQ-00432933 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ruxolitinib phosphate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Synthetic Peptides for Cancer Cachexia - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
tertomotide - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
VK-5211 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Cancer Cachexia - Recent Pipeline Updates 92
Cancer Cachexia - Dormant Projects 117
Cancer Cachexia - Discontinued Products 119
Cancer Cachexia - Product Development Milestones 120
Featured News & Press Releases 120
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 120
Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer 121
Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology 122
Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 123
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 124
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 125
Jun 25, 2012: GTx Announces Presentation On Enobosarm’s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels 125
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 126
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 127
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 128
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 129
Disclaimer 130
List Of Tables
Number of Products under Development for Cancer Cachexia, H2 2015 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2015 21
Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2015 22
Cancer Cachexia - Pipeline by Amgen Inc., H2 2015 23
Cancer Cachexia - Pipeline by Aphios Corporation, H2 2015 24
Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2015 25
Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2015 26
Cancer Cachexia - Pipeline by GTx, Inc., H2 2015 27
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2015 28
Cancer Cachexia - Pipeline by Incyte Corporation, H2 2015 29
Cancer Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2015 30
Cancer Cachexia - Pipeline by Novartis AG, H2 2015 31
Cancer Cachexia - Pipeline by Obexia AG, H2 2015 32
Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2015 33
Cancer Cachexia - Pipeline by Radius Health, Inc., H2 2015 34
Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2015 35
Cancer Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2015 36
Cancer Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2015 37
Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2015 38
Assessment by Monotherapy Products, H2 2015 39
Assessment by Combination Products, H2 2015 40
Number of Products by Stage and Target, H2 2015 42
Number of Products by Stage and Mechanism of Action, H2 2015 44
Number of Products by Stage and Route of Administration, H2 2015 46
Number of Products by Stage and Molecule Type, H2 2015 48
Cancer Cachexia Therapeutics - Recent Pipeline Updates, H2 2015 92
Cancer Cachexia - Dormant Projects, H2 2015 117
Cancer Cachexia - Dormant Projects (Contd..1), H2 2015 118
Cancer Cachexia - Discontinued Products, H2 2015 119
List Of Figures
List of Figures
Number of Products under Development for Cancer Cachexia, H2 2015 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 39
Number of Products by Top 10 Targets, H2 2015 41
Number of Products by Stage and Top 10 Targets, H2 2015 41
Number of Products by Top 10 Mechanism of Actions, H2 2015 43
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 43
Number of Products by Top 10 Routes of Administration, H2 2015 45
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 45
Number of Products by Top 10 Molecule Types, H2 2015 47
Number of Products by Stage and Top 10 Molecule Types, H2 2015 47
